{"product_id":"h-m-wnt16-shrna-lentivirus-bhv19400208","title":"h\/m WNT16 shRNA Lentivirus","description":"\u003cdiv class=\"bhp-desc\"\u003e\n\u003cstyle\u003e.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}.bhp-desc p{margin:0 0 12px}.bhp-desc ul{margin:0 0 12px 22px}.bhp-desc li{margin:0 0 6px}\u003c\/style\u003e\n\u003ch2\u003e\u003cstrong\u003eBackground\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp\u003eWNT16 (Wnt Family Member 16) is a secreted glycoprotein of the Wnt family of signaling ligands that act through Frizzled receptors to regulate both canonical (β-catenin-dependent) and non-canonical Wnt pathways. WNT16 is a notable regulator of bone mass and skeletal homeostasis, influencing cortical bone thickness, osteoblast and osteoclast activity, and fracture susceptibility, and has been identified in genome-wide studies of bone mineral density. Wnt signaling more broadly controls cell proliferation, differentiation, and tissue patterning, and its dysregulation contributes to skeletal disorders and cancer, making WNT16 a relevant target for bone biology and oncology research.\u003c\/p\u003e\n\u003ch2\u003e\u003cstrong\u003eProduct Description \u0026amp; Applications\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp\u003eThe h\/m WNT16 shRNA Lentivirus provides high-titer lentiviral particles for stable knockdown of human and mouse WNT16. The shRNA is delivered from a third-generation, self-inactivating backbone with expression from a U6 Pol III promoter, alongside a constitutively expressed fluorescent reporter (GFP or RFP, optionally with luciferase) and an antibiotic selection marker. VSV-G pseudotyping enables broad tropism, including primary, suspension, and cryopreserved cells. The shRNA is validated to achieve at least 70% knockdown using a fluorescence-based assay. The set comprises lentivirus produced from a mix of two independent validated shRNAs plus a matched scrambled-shRNA control. It is used to study WNT16 loss of function in Wnt signaling, bone biology, and cancer research.\u003c\/p\u003e\n\u003ch2\u003e\u003cstrong\u003eAbout This Product\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp\u003eThis validated shRNA lentivirus targeting WNT16 delivers a 19–20 bp shRNA from a third-generation, self-inactivating lentiviral backbone. Expression is driven from a U6 Pol III promoter, with a constitutively expressed fluorescent reporter (GFP, GFP\/Luc, RFP, RFP\/Luc) and antibiotic selection marker (Blasticidin, Puromycin) co-expressed from the same vector. VSV-G pseudotyping enables broad cell tropism, including primary, suspension, and cryopreserved cell types.\u003c\/p\u003e\n\u003cp\u003eKnockdown is validated using a proprietary bicistronic fluorescence assay in which the target mRNA is co-expressed fused to RFP alongside the shRNA-GFP construct. At least 70% reduction in RFP signal in GFP-positive cells confirms on-target activity — a more direct functional readout than transcript-level qPCR. Polyclonal stable lines can be generated by antibiotic selection within 10 days, preserving parental cell heterogeneity compared to single-clone CRISPR approaches.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"LipExoGen Biotech","offers":[{"title":"GFP \/ Puromycin \/ 5x10^6 (sh-mix) + 5x10^6 (scr-mix)","offer_id":53251625484653,"sku":"LSV-0063-SET1","price":1195.0,"currency_code":"USD","in_stock":true},{"title":"GFP \/ Puromycin \/ 5x10^6","offer_id":53362029330797,"sku":"LSV-0063-1S","price":595.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/hm-WNT16-shRNA-Figure.jpg?v=1776934211","url":"https:\/\/www.ebiohippo.com\/products\/h-m-wnt16-shrna-lentivirus-bhv19400208","provider":"BioHippo","version":"1.0","type":"link"}